FDA Transparency Has No Clear Path To Releasing Documents - Woodcock
This article was originally published in The Tan Sheet
The possible release of FDA's voluminous documents is one of the more challenging aspects - both in policies and resources - of the agency's effort to make its operations and decisions more open to the public, FDA's Janet Woodcock says
You may also be interested in...
FDA is working on an initiative to bring current advisory committee vacancies from around 30 percent down to 10 percent of its more than 600 spots without backing down from a strict conflict-of-interest policy that many see as contributing to the difficulty in filling the seats
For those wondering how many adverse events reports FDA received last month, the number of Risk Evaluation and Mitigation Strategies it cleared or the number of first generics it approved, the answers are now readily accessible
Office of New Drugs Director John Jenkins sees a possible side benefit for FDA of more efficient drug approval processes should the agency's transparency initiative lead to the public release of "complete response" letters